University of Miami-Miller School of Medicine

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the sleep disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

The professor of neurology at the Miami Miller School of Medicine detailed the clinical potential of Cognivue’s Amyloid Risk Measure (CARM) for identifying individuals with cognitive impairment likely related to amyloid pathology. [WATCH TIME: 5 minutes]

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

Michelle Bravo, MD, an assistant professor of clinical neurology at the University of Miami, provided commentary on a rare case report of a subdural hematoma linked to spontaneous intracranial hypotension caused by a refractory CSF leak.

The professor of human genetics at the University of Miami discussed the significance of various genetic factors in Alzheimer risk and highlighted ongoing research, therapeutic challenges as well as the need for global collaboration. [WATCH TIME: 10 minutes]

The professor of human genetics at the University of Miami talked about the Alzheimer's Disease Sequencing Project which aims to provide diverse genetic data to identify therapeutic targets for Alzheimer disease. [WATCH TIME: 10 minutes]

The associate professor of clinical neurology at University of Miami Miller School of Medicine discussed the implications of findings from a recent post hoc analysis on midazolam and the need for inclusive research in assessing the efficacy of seizure rescue treatments. [WATCH TIME: 3 minutes]

The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes]

In a recent post hoc analysis, findings showed that nearly 50% of patients treated with 1 or 2 doses of midazolam experienced return to full baseline functionality in 1 hour of administration.

At the 2023 MDA conference, the professor for human genetics and neurology at the University of Miami Miller School of Medicine talked about the role of genetics in neuromuscular diseases and potential therapies. [WATCH TIME: 5 minutes]

James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies and Alzheimer disease. [WATCH TIME: 4 minutes]

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed how a new innovative tool can further characterize cognitive status and improve evaluation of agents in development for Alzheimer disease. [WATCH TIME: 2 minutes]

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]

The associate professor of neuropsychology at the University of Miami Miller School of Medicine provided insight on how persistent impairments seen on a cognitive screening tool may differentiate cognitive status. [WATCH TIME: 6 minutes]

The medical student at Nova Southeastern University provided insight on a new innovative tool called the Cognitive Stress Test that can help distinguish different cognitive states for older adults. [WATCH TIME: 6 minutes]

The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided context on the influence that genetics will have in drug development for Alzheimer disease in the coming years.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami detailed a new international initiative that expands on the genetic backgrounds of people of Hispanic and African ancestry. [WATCH TIME: 4 minutes]

The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed the background behind a new initiative geared towards understanding genetic differences of underrepresented groups. [WATCH TIME: 6 minutes]

The double-blind, placebo-controlled, randomized trial will evaluate CT1812, a small molecule therapeutic designed to address the dual assault from α-synuclein and amyloid-ß oligomers in patients with dementia with Lewy bodies.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed non-APOE–related genetic correlations between different groups of individuals and Alzheimer disease. [WATCH TIME: 5 minutes]

The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided insight on the outlook on genetics and gene-based therapies for Alzheimer disease. [WATCH TIME: 3 minutes]

The director of the Sleep Disorders program at the University of Miami discussed his research regarding the association of sleep disordered breathing and total brain volumes in Latino individuals. [WATCH TIME: 3 minutes]

The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.

James E. Galvin, MD, MPH, provided thoughts on the struggles to raise dementia literacy and awareness in underserved, rural, ethnically diverse populations through the ongoing pandemic.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the current understanding of COVID-19 and its associations with cognitive decline and Alzheimer disease.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed projects dedicated towards improving dementia recognition and care within multicultural communities.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the real-world level of dementia education and where it needs improvement.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed employing the MoCA-T app as a means of cognitive screening in rural and ethnically diverse populations.